Galderma Receives FDA Approval for Restylane Defyne for Chin Augmentation

Photo credit: Galderma

Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 2016 by the FDA for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds, in subjects over age 21. "This marks Galderma's 8th FDA aesthetics approval in 5 years, illustrating our long-term commitment to advancing aesthetics through new innovation," says Alisa Lask, general manager and vice president of the U.S. Aesthetics Business at Galderma. "The chin is the foundational anchor of the face that brings the rest of your features into balance.8 Consumers can now address the chin with a non-surgical, safe option from a brand that uses cutting-edge XpresHAn Technology to shape and produce long-lasting results."

For more information about Restylane Defyne for chin, visit www.restylaneusa.com.

RELATED STORIES

Galderma Announces Launch Of Face For Change Program

Galderma Aesthetics Offers Virtual Reality Education Platform

Galderma Aesthetics's Aspire Rewards Program Partners With Aesthetic Record, PatientNOW, and Symplast